BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update

BioAtla, Inc. (NASDAQ:BCAB) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totalling 4,400,000 shares, a growth of 11.4% from the December 31st total of 3,950,000 shares. Based on an average trading volume of 1,120,000 shares, the short-interest ratio is currently 3.9 days.

Institutional Trading of BioAtla

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new stake in shares of BioAtla during the 2nd quarter worth $872,000. Massachusetts Financial Services Co. MA raised its holdings in shares of BioAtla by 5.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock worth $1,002,000 after acquiring an additional 28,133 shares in the last quarter. Bank of Montreal Can lifted its holdings in shares of BioAtla by 55.1% during the 2nd quarter. Bank of Montreal Can now owns 404,198 shares of the company’s stock valued at $554,000 after buying an additional 143,521 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of BioAtla during the 3rd quarter valued at $623,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of BioAtla by 28.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 333,858 shares of the company’s stock valued at $458,000 after purchasing an additional 73,598 shares during the last quarter. 77.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright downgraded shares of BioAtla from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 13th.

BioAtla Price Performance

NASDAQ:BCAB traded down $0.02 during mid-day trading on Monday, reaching $0.45. The stock had a trading volume of 1,186,415 shares, compared to its average volume of 1,048,391. The company has a market capitalization of $21.96 million, a price-to-earnings ratio of -0.27 and a beta of 1.14. BioAtla has a 1-year low of $0.43 and a 1-year high of $4.02. The stock’s 50 day simple moving average is $0.92 and its two-hundred day simple moving average is $1.50.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.12. The firm had revenue of $11.00 million during the quarter. During the same period last year, the business earned ($0.70) EPS. Sell-side analysts anticipate that BioAtla will post -1.46 EPS for the current fiscal year.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.